Could Cymabay Therapeutics, Inc. (CBAY) Decline After Today’s Huge Increase?

February 15, 2018 - By Hazel Jackson

The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) is a huge mover today! The stock increased 8.77% or $1.18 during the last trading session, reaching $14.64. About 2.03 million shares traded or 165.47% up from the average. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since February 15, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.
The move comes after 8 months positive chart setup for the $811.74M company. It was reported on Feb, 15 by Barchart.com. We have $15.52 PT which if reached, will make NASDAQ:CBAY worth $48.70M more.

Analysts await Cymabay Therapeutics, Inc. (NASDAQ:CBAY) to report earnings on March, 22. They expect $-0.13 EPS, up 56.67 % or $0.17 from last year’s $-0.3 per share. After $-0.21 actual EPS reported by Cymabay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -38.10 % EPS growth.

Cymabay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

Among 7 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 21 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Monday, January 30. The stock has “Buy” rating by Leerink Swann on Tuesday, November 28. H.C. Wainwright maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Wednesday, January 24. H.C. Wainwright has “Buy” rating and $18 target. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, March 30 report. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given on Monday, September 11 by Piper Jaffray. The stock has “Neutral” rating by H.C. Wainwright on Wednesday, January 4. The rating was maintained by Oppenheimer on Wednesday, January 10 with “Buy”. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Cantor Fitzgerald on Wednesday, October 25. The company was maintained on Monday, July 17 by Piper Jaffray. The stock has “Buy” rating by Roth Capital on Thursday, January 25.

More news for Cymabay Therapeutics, Inc. (NASDAQ:CBAY) were recently published by: Streetinsider.com, which released: “CymaBay Therapeutics (CBAY) Commences Common Stock Offering” on January 29, 2018. Marketwatch.com‘s article titled: “Opinion: 4 charts to watch as tech stocks rebound” and published on February 14, 2018 is yet another important article.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $811.74 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.